Literature DB >> 33539779

MicroRNA155 Plays a Critical Role in the Pathogenesis of Cutaneous Leishmania major Infection by Promoting a Th2 Response and Attenuating Dendritic Cell Activity.

Sanjay Varikuti1, Chaitenya Verma1, Gayathri Natarajan1, Steve Oghumu1, Abhay R Satoskar2.   

Abstract

Interferon (IFN)-γ is indispensable in the resolution of cutaneous leishmaniasis (CL), while the Th2 cytokines IL-4, IL-10, and IL-13 mediate susceptibility. A recent study found that miR155, which promotes CD4+ Th1 response and IFN-γ production, is dispensable in the control of Leishmania donovani infection. Here, the role of miR155 in CL caused by L. major was investigated using miR155-deficient (miR155-/-) mice. Infection was controlled significantly quicker in the miR155-/- mice than in their wild-type (WT) counterparts, indicating that miR155 contributes to the pathogenesis of CL. Faster resolution of infection in miR155-/- mice was associated with increased levels of Th1-associated IL-12 and IFN-γ and reduced production of Th2- associated IL-4, IL-10, and IL-13. Concentrations of IFN-γ+CD8+ T cells and natural killer cells in draining lymph nodes were significantly higher in the L. major-infected miR155-/- mice than in the infected WT mice, as indicated by flow-cytometry. After in vitro IFN-γ stimulation, nitric oxide and IL-12 production were increased, IL-10 production was decreased, and parasite clearance was enhanced in L. major-infected miR155-/- DCs compared to those in WT DCs. Furthermore, IFN-γ production from activated miR155-/- T cells was significantly enhanced in L. major-infected miR155-/- DCs. Together, these findings demonstrate that miR155 promotes susceptibility to CL caused by L. major by promoting Th2 response and inhibiting DC function.
Copyright © 2021 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33539779      PMCID: PMC8132173          DOI: 10.1016/j.ajpath.2021.01.012

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  46 in total

1.  Regulation of dendritic cell maturation and function by Bruton's tyrosine kinase via IL-10 and Stat3.

Authors:  Yuko Kawakami; Naoki Inagaki; Shahram Salek-Ardakani; Jiro Kitaura; Hiroyuki Tanaka; Koichi Nagao; Yu Kawakami; Wenbin Xiao; Hiroichi Nagai; Michael Croft; Toshiaki Kawakami
Journal:  Proc Natl Acad Sci U S A       Date:  2005-12-21       Impact factor: 11.205

2.  miR-155 activates cytokine gene expression in Th17 cells by regulating the DNA-binding protein Jarid2 to relieve polycomb-mediated repression.

Authors:  Thelma M Escobar; Chrysi Kanellopoulou; David G Kugler; Gokhul Kilaru; Cuong K Nguyen; Vijayaraj Nagarajan; Ravikiran K Bhairavabhotla; Daniel Northrup; Rami Zahr; Patrick Burr; Xiuhuai Liu; Keji Zhao; Alan Sher; Dragana Jankovic; Jinfang Zhu; Stefan A Muljo
Journal:  Immunity       Date:  2014-05-22       Impact factor: 31.745

3.  MicroRNA-155 promotes autoimmune inflammation by enhancing inflammatory T cell development.

Authors:  Ryan M O'Connell; Daniel Kahn; William S J Gibson; June L Round; Rebecca L Scholz; Aadel A Chaudhuri; Melissa E Kahn; Dinesh S Rao; David Baltimore
Journal:  Immunity       Date:  2010-09-30       Impact factor: 31.745

4.  Staphylococcal enterotoxin B-induced microRNA-155 targets SOCS1 to promote acute inflammatory lung injury.

Authors:  Roshni Rao; Sadiye Amcaoglu Rieder; Prakash Nagarkatti; Mitzi Nagarkatti
Journal:  Infect Immun       Date:  2014-04-28       Impact factor: 3.441

Review 5.  Mir-155, a central modulator of T-cell responses.

Authors:  Evan F Lind; Pamela S Ohashi
Journal:  Eur J Immunol       Date:  2014-01       Impact factor: 5.532

6.  CD86 has sustained costimulatory effects on CD8 T cells.

Authors:  Ian J Thomas; Liliana G Petrich de Marquesini; Rommel Ravanan; Richard M Smith; Sylvie Guerder; Richard A Flavell; David C Wraith; Li Wen; F Susan Wong
Journal:  J Immunol       Date:  2007-11-01       Impact factor: 5.422

7.  Transcriptional inhibition of interleukin-12 promoter activity in Leishmania spp.-infected macrophages.

Authors:  Asha Jayakumar; Robyn Widenmaier; Xiaojing Ma; Mary Ann McDowell
Journal:  J Parasitol       Date:  2008-02       Impact factor: 1.276

Review 8.  The early interaction of Leishmania with macrophages and dendritic cells and its influence on the host immune response.

Authors:  Dong Liu; Jude E Uzonna
Journal:  Front Cell Infect Microbiol       Date:  2012-06-12       Impact factor: 5.293

9.  HIV-induced type I interferon and tryptophan catabolism drive T cell dysfunction despite phenotypic activation.

Authors:  Adriano Boasso; Andrew W Hardy; Stephanie A Anderson; Matthew J Dolan; Gene M Shearer
Journal:  PLoS One       Date:  2008-08-13       Impact factor: 3.240

10.  Inhibition of IFN-γ-Induced Nitric Oxide Dependent Antimycobacterial Activity by miR-155 and C/EBPβ.

Authors:  Yongwei Qin; Qinglan Wang; Youlang Zhou; Yinong Duan; Qian Gao
Journal:  Int J Mol Sci       Date:  2016-04-08       Impact factor: 5.923

View more
  3 in total

1.  DnaJ, a promising vaccine candidate against Ureaplasma urealyticum infection.

Authors:  Fangyi Guo; Yanhong Tang; Wenjun Zhang; Hongxia Yuan; Jing Xiang; Wenyou Teng; Aihua Lei; Ranhui Li; Guozhi Dai
Journal:  Appl Microbiol Biotechnol       Date:  2022-10-21       Impact factor: 5.560

Review 2.  Determinants of Innate Immunity in Visceral Leishmaniasis and Their Implication in Vaccine Development.

Authors:  Greta Volpedo; Thalia Pacheco-Fernandez; Parna Bhattacharya; Timur Oljuskin; Ranadhir Dey; Sreenivas Gannavaram; Abhay R Satoskar; Hira L Nakhasi
Journal:  Front Immunol       Date:  2021-10-12       Impact factor: 7.561

3.  Centrin-deficient Leishmania mexicana confers protection against New World cutaneous leishmaniasis.

Authors:  Greta Volpedo; Thalia Pacheco-Fernandez; Erin A Holcomb; Wen-Wei Zhang; Patrick Lypaczewski; Blake Cox; Rebecca Fultz; Chelsea Mishan; Chaitenya Verma; Ryan H Huston; Abigail R Wharton; Ranadhir Dey; Subir Karmakar; Steve Oghumu; Shinjiro Hamano; Sreenivas Gannavaram; Hira L Nakhasi; Greg Matlashewski; Abhay R Satoskar
Journal:  NPJ Vaccines       Date:  2022-03-02       Impact factor: 7.344

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.